Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Decibel Therapeutics Shares Continue to Rally After Good Study Data >DBTX
12:58 pm ET June 29, 2022 (Dow Jones) Print
By Colin Kellaher
Shares of Decibel Therapeutics Inc. surged more than 30% on Wednesday, extending Tuesday's gains after the clinical-stage biotechnology company reported positive study results.
The Boston company on Tuesday said interim data from a Phase 1b study of DB-020 support continued development of the drug in the protection against ototoxicity, or hearing loss, in cancer patients receiving cisplatin chemotherapy.
Decibel said 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from the side effect in their ear treated with DB-020.
In a research note, Citi analyst Neena Bitritto-Garg, who has a "buy" rating and a $15 target price on Decibel shares, said the study data mark "a clear win" the company.
The analyst also noted that Decibel remains focused on its earlier-stage gene-therapy portfolio, with an ultimate goal of licensing DB-020 to a company with an oncology sales force.
Decibel shares, which rose 18.3% on Tuesday, were recently changing hands at $3.52, up 32.9%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Marathon Digital shares are trading lower after the company announced that its mining operations were impacted by a storm that passed through Montana earlier this month, leaving operations in the region without power.
12:51pm ET 06/29/22
LiveOne Shares Soar 18% On 4Q Results, Cost and Expense Reductions
5:03 pm ET June 28, 2022 (Dow Jones) Print
By Denny Jacob
LiveOne Inc. shares jumped 18% to 90 cents in after-hours trading Tuesday after the company narrowed its loss in the fourth quarter and said it is cutting costs that will increase its annual cost savings to over $23 million for fiscal 2023.
The digital media company, which distributes and monetizes music- and video-related content, narrowed its loss to $8.8 million, or a loss of 11 cents a share, for the three months ended March 31, from a loss of $15.4 million, or a loss of 20 cents a share, a year earlier.
Revenue rose to $23.4 million from $21 million.
The company said it is implementing additional cost and expense reductions from both operations and corporate overhead. LiveOne said it expects this to increase its previously implemented annual cost savings to over $23 million in its fiscal year ending March 31, 2023.
LiveOne said it also settled about $5.5 million in payables and short-term liabilities for the current quarter ending Thursday.
Chief Executive Robert Ellin said its audio business continues to improve due to growth of paid members through partnerships as well as an increase in advertising and sponsorships. Mr. Ellin also said its cost reductions has allowed the company to accelerate its timeline to achieving positive adjusted earnings before interest, taxes, depreciation and amortization to the current quarter.
The company said it is continuing to explore strategic alternatives in order to enhance shareholder value, which it first announced in January 2021.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
LiveOne, Inc., formerly LiveXLive Media, Inc., is an interactive music, sports, and entertainment subscription platform delivering content and livestreams from the artists. The Company’s platform provides livestream and on-demand audio, video, and podcast/vodcast content in music, comedy and pop culture. Its brands include PodcastOne, SlackerOne, ReactOne, PersonalizedMerchOne and StudioOne. Its StudioOne provides subscription and advertising streaming music service. Its ReactOne produces original music-related content, including live music festivals, concerts and events. Its PersonalizedMerchOne operates as retailer of personalized merchandise and gifts. Its PodcastOne operates a podcasting platform.
EVFM > 1.53 > Huge news out 20 minutes ago: Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi(R)
6:48 am ET June 28, 2022 (PR Newswire)
We all here made multiple profitable trades with FEMY. We all made multiple profitable trades with EVFM. > Relax! ..... Good luck with your research.
FEMY ??? They don't have anything on the market as of yet, all they have is preclinical research for fertility drugs,,, NOT BIRTH CONTROL> EVFM Phexxi IS FDA approved and on the market and sales are growing exponentially. Do your research peeps.
FEMY > Maxim Group initiated coverage on Femasys Inc (NASDAQ:FEMY) with a Buy rating. The price target for Femasys is set to $5.00.
FEMY going multi-dollars ! Investors are discovering company as well as the significant % gain in share price .
$FEMY BOOOOM
TBLT CLOSES $6 MILLION DOLLAR OFFERING! > $$$$$
TBLT > definitely a $weet upside run!
TBLT > 3.28 > massive 10 million vol. premarket.
PREMARKET VOLUME > 10 MILLION + > $$$$$
TBLT IS A GREAT $$$$$ OPPORTUNITY.
TBLT > 3.10
TBLT > 2.91
SIGA > SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX(R) (Tecovirimat)
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $13 million of procurement orders for oral TPOXX (tecovirimat), including $11 million for initial procurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region that has an established contract for oral TPOXX (tecovirimat).
"Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness," said Phil Gomez, CEO of SIGA. "We expect a portion of the courses of oral TPOXX delivered under these orders will be used for the treatment of active monkeypox cases and represent a first step in the response to this outbreak by the global public health community. By increasing both the scale and scope of TPOXX stockpiling, countries can be better prepared for the outbreak risks of smallpox, monkeypox, and other viruses in the orthopoxvirus family of viruses and make sure that patients are able to access a proven safe and effective treatment."
VERV > Verve Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and $48 price target.
VERV IS A GREAT $$$$$ OPPORTUNITY.
SIGA IS A GREAT $$$$$ OPPORTUNITY.
C'mon SIGA, let's go bigga! > SIGA is a great $$$$$ opportunity.
SIGA > up 7% @ 13.31
You bet! SIGA going much higher > CAMBRIDGE, Mass. – June 22, 2022 – The World Health Network (WHN) today announced that they are declaring the current monkeypox outbreak a pandemic given that there are now 3,417 confirmed Monkeypox cases reported across 58 countries and the outbreak is rapidly expanding across multiple continents. The outbreak will not stop without concerted global action. Even with death rates much lower than smallpox, unless actions are taken to stop the ongoing spread—actions that can be practically implemented—millions of people will die and many more will become blind and disabled.
The essential purpose of declaring a pandemic is to achieve a concerted effort across multiple countries or over the world to prevent widespread harm. The definition of a pandemic is an infectious disease growing over a wide area, crossing international boundaries, and usually affecting a large number of people. The accelerating growth across multiple continents, and the need for a concerted action to stop it, meets both the criteria, and the essential purpose, for declaration of a pandemic. Concerted global action is needed.
SIGA > "now a pandemic " > CAMBRIDGE, Mass. – June 22, 2022 – The World Health Network (WHN) today announced that they are declaring the current monkeypox outbreak a pandemic given that there are now 3,417 confirmed Monkeypox cases reported across 58 countries and the outbreak is rapidly expanding across multiple continents. The outbreak will not stop without concerted global action. Even with death rates much lower than smallpox, unless actions are taken to stop the ongoing spread—actions that can be practically implemented—millions of people will die and many more will become blind and disabled.
The essential purpose of declaring a pandemic is to achieve a concerted effort across multiple countries or over the world to prevent widespread harm. The definition of a pandemic is an infectious disease growing over a wide area, crossing international boundaries, and usually affecting a large number of people. The accelerating growth across multiple continents, and the need for a concerted action to stop it, meets both the criteria, and the essential purpose, for declaration of a pandemic. Concerted global action is needed.
CAMBRIDGE, Mass. – June 22, 2022 – The World Health Network (WHN) today announced that they are declaring the current monkeypox outbreak a pandemic given that there are now 3,417 confirmed Monkeypox cases reported across 58 countries and the outbreak is rapidly expanding across multiple continents. The outbreak will not stop without concerted global action. Even with death rates much lower than smallpox, unless actions are taken to stop the ongoing spread—actions that can be practically implemented—millions of people will die and many more will become blind and disabled.
The essential purpose of declaring a pandemic is to achieve a concerted effort across multiple countries or over the world to prevent widespread harm. The definition of a pandemic is an infectious disease growing over a wide area, crossing international boundaries, and usually affecting a large number of people. The accelerating growth across multiple continents, and the need for a concerted action to stop it, meets both the criteria, and the essential purpose, for declaration of a pandemic. Concerted global action is needed.
PEV > 7.86 up 34%
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
Elon Musk > " GIGANTIC MONEY FURNACE "
ELON MUSK JUST SAID: "Both Berlin and Austin factories are gigantic money furnaces right now"!!!!!!!
EXXONMOBIL > One hour special on CNBC tonight @ 8:00 pm EST.
MOSCOW, June 22 (Reuters) - Two drones flying from the direction of Ukraine hit a major Russian oil refinery near the border on Wednesday, the plant said, sending a ball of flame and black smoke billowing into the sky and prompting the plant to suspend production.
Russian regions bordering Ukraine have reported numerous attacks and shelling after Moscow sent its troops into its former Soviet neighbour on Feb. 24 for what it calls a "special military operation".
The Novoshakhtinsk oil refinery in Russia's Rostov region said the first drone struck at 8.40 a.m. (0540 GMT) hitting acrude distillation unit, triggering a blast and ball of fire.
The second strike at 0623 GMT was aimed at crude oil reservoirs at the refinery, the largest supplier of oil products in southern Russia, but caused no fire, the plant said. No one was injured.
"As a result of terrorist actions from the Western border of the Rostov region, two unmanned aerial vehicles struck at the technological facilities of Novoshakhtinsk," the plant said.
"Staff have been evacuated and technological equipment has been stopped to assess the damage."
Rostov's regional governor, Vasily Golubev, said the oil refinery suspended operations. He said fragments of two drones had been found at the refinery.
Social media footage showed a drone flying towards the refinery, located just 8 km (5 miles) from the border with Ukraine, before a large ball of flame rose up, prompting exclamations from those near the camera.
The refinery has an annual capacity of up to 7.5 million tonnes, and started operations in 2009.
Russia's energy ministry said the fire had not affected gasoline and diesel supplies to consumers in southern Russia.
Russia is also investigating the cause of a large fire that erupted
USWS @ 1.05
We'll see 1.21 today!
USWS @ .97
Back in MARA @ 6.96 >
ProFrac Holding Corp. To Acquire U.S. Well Services in for ~$1.21/Share in All-Stock Deal.
USWS
USWS up 29% @ .93 > ProFrac Holding Corp. To Acquire U.S. Well Services in for ~$1.21/Share in All-Stock Deal.
USWS
VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. Blocking OspA inhibits the bacterium’s ability to leave the tick and infect humans. The vaccine covers the six most common OspA serotypes expressed by Borrelia burgdorferi sensu lato species that are prevalent in North America and Europe. VLA15 has demonstrated a strong immunogenicity and safety profile in pre-clinical and clinical studies so far. The program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 20172. Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA151.
26.50
SYM up 56% @ 26.50